Healthcare >> CEO Interviews >> October 3, 2003
JONATHAN KIL MD is President, CEO & Director of Sound Pharmaceuticals,
Inc. Dr. Kil has an extensive background in auditory and cell cycle
biology, which translates directly into the scientific platforms of SPI.
He has served as the principal investigator on several NIH grants
including an SBIR phase II award for auditory hair cell regeneration. In
1998, Dr. Kil co-founded Otogene, the first inner ear biopharmaceutical
company, using anti p27Kip1 technology that he developed with
investigators at the Fred Hutchinson Cancer Research Center. As
President, CEO, and CSO he transitioned its basic R&D technology into a
pre-clinical drug development platform. He left in February of 2001 and
co-founded SPI in July of 2001. Dr. Kil earned his BA from the
University of California, Irvine, his MD from the University of Virginia
and completed his post-doctoral training at the University of
Washington. Profile
Pharmaceuticals and a picture of things as they are now?
Dr. Kil: Sound Pharmaceuticals is an early-stage biopharm company,
